CVKD Stock Forecast & Price Target

Cadrenal Therapeutics Inc. has entered a significant collaboration with Abbott to support the Phase 3 TECH-LVAD trial, which aims to evaluate the efficacy and safety of tecarfarin in patients using left ventricular assist devices (LVADs), highlighting the potential for advancing its clinical development. Furthermore, the completion of the manufacturing transition of tecarfarin’s active pharmaceutical ingredient (API) to a U.S.-based facility is expected to enhance both the clinical and regulatory development strategy as well as improve supply chain security. These developments indicate a strong commitment to addressing unmet needs in anticoagulation therapy, positioning Cadrenal favorably within its market segment.

Cadrenal Therapeutics is facing significant challenges that contribute to a negative outlook, primarily due to the potential for failed or inconclusive clinical trials that could undermine the development of its drug candidate, tecarfarin. Additionally, the company reported a cash position of only $7.3 million at the end of the first quarter of 2025, raising concerns about its ability to secure adequate funding for continued operations. Furthermore, reliance on dilutive capital raises poses a risk to shareholders, potentially affecting future equity values.